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Diabetes/obesity treatmentGPR119 is a Gas-coupled lipid-sensor in the gut, where it mediates release of incretin hormones from the
enteroendocrine cells and in pancreatic a-cells, where it releases insulin. Naturally occurring lipids such
as monoacylglycerols (MAGs) and N-acylethanolamines (NAEs), like oleoylethanolamide (OEA), activate
GPR119, and multiple synthetic ligands have been described. Here, we extend the GPR119 signaling pro-
file to Gaq and Gai in addition to b-arrestin recruitment and the downstream transcription factors CRE
(cAMP response element), SRE (serum response element) and NFAT (nuclear factor of activated T cells).
The endogenous OEA and the synthetic AR231453 were full agonists in all pathways except for NFAT,
where no ligand-modulation was observed. The potency of AR231453 varied <16-fold (EC50 from 6 to
95 nM) across the different signaling pathways, whereas that of OEA varied >175-fold (from 85 nM to
15 lM) indicating a biased signaling for OEA. The degree of constitutive activity was 1–10%, 10–30%
and 30–70% of OEA-induced Emax in Gai, Gaq and Gas-driven pathways, respectively. This coincided with
the lowest and highest OEA potency observed in Gai and Gas-driven pathways, respectively. Incubation
for 2 h with the 2-MAG-lipase inhibitor JZL84 doubled the constitutive activity, indicating that endoge-
nous lipids contribute to the apparent constitutive activity. Finally, besides being an agonist,
AR231453 acted as a positive allosteric modulator of OEA and increased its potency by 54-fold at
100 nM AR231453. Our studies uncovering broad and biased signaling, masked constitutive activity by
endogenous MAGs, and ago-allosteric properties of synthetic ligands may explain why many GPR119
drug-discovery programs have failed so far.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction response to diet; deficits that are even more pronounced in obeseThe number of people suffering from type 2 diabetes mellitus
(T2DM) has escalated worldwide as a consequence of unhealthy
lifestyle and obesity [1]. T2DM is characterized by insulin-
resistance, decreased insulin secretion from the pancreatic b-cells
and loss of intestinal glucagon-like-peptide (GLP)-1 release inindividuals [2]. The G protein-coupled receptor (GPR) 119 acts as
a lipid-sensor in the gut, where it induces the release of incretin
hormones, GLP-1 and glucose-dependent insulinotropic polypep-
tide (GIP) from the intestinal L and K-cells, respectively, in response
to dietary lipids [3–6]. Besides its expression in intestinal enteroen-
docrine cells (EEC), GPR119 is also expressed in pancreatic b-cells,glucose-
l; MAGL,
element;
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[7–9]. GPR119 in pancreas may possibly be stimulated by
2-monoacylglycerol (MAG) generated by lipoprotein lipase [10].
GPR119 couples to Gas with high constitutive activity and in
response to lipid-based agonists like lysophosphatidylcholines
(LPCs), oleic-acid containing N-acyl-amino compounds like
N-oleoyldopamine (OLDA) and N-acylethanolamines (NAEs)
[3,8,9,11–14]. Of these, the oleic-acid containing OEA is the most
potent lipid-based GPR119 agonist [3]. It stimulates cAMP
accumulation in GPR119 transfected cells with high potency
(EC50 of 0.2–2.9 lM) [3,12] and releases GLP-1 in vitro from
GLUTag-cells, an EEC cell-linewith endogenous GPR119 expression,
and in vivo after intraluminal injection in mice [15]. Monoacylglyc-
erols (MAGs) such as 2-oleoyl glycerol (2-OG), which is generated in
high amounts during digestion of the diet, also activate GPR119 as
shown in recent in vivo studies in humans, where ingested 2-OG
stimulated GLP-1 release [3,4]. Similar experiments in wild type
and GPR119-deficient mice proved that the GLP-1 secretion
induced by 2-OG (and the more stable ether analog of 2-OG) indeed
is mediated via GPR119 activation [5].
The massive interest in GPR119 as a pharmaceutical target for
the treatment of T2DM and obesity has resulted in numerous syn-
thetic GPR119 ligands, for recent reviews see [14,16,17]. In 2007,
the prototypical GPR119 agonist, AR231453, was published as a
GPR119-specific glucose-dependent insulin secretagogwith similar
efficacy as GLP-1 [8], and shortly thereafter was shown to stimulate
incretin hormone release in mice [13]. This inspired many compa-
nies to create new GPR119 agonists, though only few have reached
clinical trials [16,18,19]. GPR119 antagonists and inverse agonists
have also been described, like AR436352, used in the present study.
The signaling through Gas is well established for GPR119 [3,8,
9,11–14,20–23] as measured by cAMP accumulation and/or
downstream activation of the transcription factor CREB (cAMP
response element binding protein) in response to both lipids (e.g.
OEA, OLDA, LPC, 2-OG) and multiple synthetic GPR119 agonists
[3,8,9,11,12,20,24,25]. In addition, calcium release has been
described for ligand-mediated GPR119 activation [24,26], whereas
G protein-independent signaling via b-arrestin recruitment has
only been sparsely described in the patent literature [27].
Here, we present an in depth analysis of the signaling profile of
GPR119 with and without ligand addition. We compare the activity
of the endogenous lipid OEA and the synthetic non-lipid-based
agonist AR231453 through G protein-dependent and -
independent pathways to search for signaling bias. Given their
structural differences, and only partly overlapping binding sites
[28], these two ligands were furthermore combined in order to
study allosteric modulation properties. The synthetic GPR119
inverse agonist AR436352 [28] was included to study ligand-
modulation of the constitutive activity at the transcriptional
activity level (CRE, SRE and NFAT). As the activity of lipid-
receptors may be under influence of endogenous lipids revealing
apparent constitutive activity, as shown for GPR40 and EBI2 (also
known as GPR183) [29–32] – we tested whether this was the case
for GPR119 by addition of two inhibitors of the enzymes that
degrade the endogenous GPR119 agonists MAGs and NAEs. Our
studies expand the basic pharmacological knowledge of GPR119,
and introduce signaling bias, allosteric actions and apparent con-
stitutive activity as important traits for this receptor.
2. Materials and methods
2.1. Materials
OEA (Cayman Chemicals, Ann Arbour, USA), AR231453
(C21H24FN7O5S), AR436352 (C20H18FN5O4S) (Arena Pharmaceu-
tical Inc., San Diego, USA) and Glucose-dependent insulinotropicpolypeptide (GIP) (Human, H-5645, Bachman, Germany) were all
dissolved in 1% DMSO (Sigma–Aldrich, MO, USA). Fatty acid amide
hydrolase (FAAH) inhibitor URB597 and monoacylglycerol lipase
(MAGL) inhibitor JZL184 (Cayman Chemicals, Ann Arbour, USA)
[33,34] were dissolved in 0.5% DMSO. GPR119 and the human
GIP receptor were cloned into the pcDNA3 vector. Gqs5 that turns
Gas-coupling into a Gaq signal was used as a positive control in
IP3 turnover assay [35]. Gqi5 and Gqi4myr that both turn Gai
coupling into a Gaq signal were used to test for Gai coupling of
GPR119. The three chimeric G proteins Gqs5, Gqi5 and
Gqi4myr were kindly provided by 7TM pharma A/S (Hørsholm,
Denmark).
2.2. Cell culture and transfections
COS-7 cells were cultured in Dulbecco’s modified Eagle’s med-
ium (DMEM) 1885 (Gibco, Life Technologies, USA) supplemented
with 10% Fetal Bovine Serum (FBS) (Invitrogen, CA, USA), 26 mg/
ml L-glutamine and 180 IU/ml penicillin + 45ug/L streptomycin
(Pen Strep, P/S) (Life Technologies, CA, USA) at 37 C and 10%
CO2. HEK293 cells were cultured in DMEM with 10% FBS and Pen-
Step as for the COS-7 cells, at 37 C and 10% CO2. HEK293 medium
for transcription factor reporter assay was DMEM, (Gibco, Life
Technologies, USA) with 0.5% FBS for SRE and 10% FBS for both
CREB and NFAT. U2OS cells, stably expressing b-arrestin2 coupled
to the large b-galactosidase fragment and GPR119, were cultured
in DMEM alpha + GlutaMAXTM-I (Gibco, Aukland, New Zeeland),
10% FBS, 26 mg/ml L-glutamine, 180 IU/ml penicillin + 45ug/L
streptomycin (PenStrep) at 37 C and 10% CO2. COS-7 cells were
transiently transfected with GPR119 or pcDNA3 by the calcium
phosphate transfection method for 5 h at 37 C, 10% CO2 [36] for
the cAMP assay and the inositol tris-phosphate (IP3) turnover
assay. For the luciferase reporter assays and the calcium assay,
HEK293 cells were transfected for 5 h using Lipofectamine2000
and serum free optiMEM (both from Life Technology (TermoFis-
cher), MA USA). For the luciferase reporter assays, cells were co-
transfected with GPR119 DNA or pcDNA3 and cis reporter SRE/
NFAT luciferase or trans reporter CREB luciferase.
2.3. cAMP accumulation assay
COS-7 cells were transfected with 40 lg GPR119 DNA or
pcDNA3 per 175 cm2 flask. One day after transfection, the cells
were seeded out (35.000 cell/well) in a 96 well white plate (Perkin
Elmer, Massachusetts, USA). The cells were washed twice and incu-
bated for 30 min at 37 C with HBS + 1 mM IBMX (Sigma Aldrich,
USA). Increasing concentrations of agonists were added to the cells
and incubated for 30 min. Upon co-administration with the two
agonists, a 5 min pre-incubation period was introduced for the
agonist given in a fixed concentration before addition of increasing
concentration of the other agonist. The enzyme inhibitors, URB597
(fatty acid amino hydrolase (FAAH) inhibitor) and JZL84 (monoa-
cylglycerol lipase (MAGL) inhibitor) were added for 2 or 24 h at
37 C. The Hithunter cAMP XS+ procedure (DiscoveRx, Fremont,
USA) was carried out following the manufacturers’ description.
2.4. Calcium mobilization experiment
HEK293 cells were transfected with 5 ng GPR119 DNA or
pcDNA3 per well in black 96 well plate (35,000/well) (Corning
Incorporated, Berlin, Germany). One day after transfection the
loading buffer, containing calcium sensitive fluorophore, Fluo-4,
(FLIPR calcium assay kit) (Invitrogen CA, USA), was added to the
cell plate and incubated for 1 h at 37 C. Agonists were prepared
in a reagent plate. 25 ll were transferred to the cell plate, while
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2.5. b-Arrestin recruitment experiment
b-Arrestin recruitment was measured using a Pathhunter
barrestin assay (DiscoveRx, Fremont, USA). U20S were cultured in
minimal essential medium (MEM)a supplemented with GlutaMAX
(1x) (Gibco, Aukland, New Zeeland) and adjusted with 10% (v/v)
FBS, 1% (v/v) P/S and 0.5% (v/v) hygromycin B. Cells were seeded
out (35,000/well) in 96 well white plates (Perkin Elmer,
Massachusetts, USA). Agonist stimulation was performed for
90 min at 37 C followed by incubation with the Detection Reagent
Solution for 1 h. The chemiluminescence was measured at the
EnVision 2104multi lab reader (Perkin Elmer, Massachusetts, USA).
2.6. IP3 turnover experiment
COS-7 cellswere transfectedwith 40 lgGPR119 or pcDNA3with
or without 30 lg of the chimeric proteins Gqs5, Gqi5 or
Gqi4myr per 175m2 flask. One day after transfection, cells were
incubated with Myo-[2 3H(N)]-inositol (Perkin Elmer,
Massachusetts, USA) for 24 h and afterward seeded out in a white
bottom, 96 well plate (35,000/well) (Perkin Elmer, Massachusetts,
USA). Agonists were added in HBSS + 10 mM LiCl to the cells for
90 min at 37 C. The cells were lyzed with 10 mM formic acid, and
incubated with SPA-YSI beads (1 mg/well) (Perkin Elmer,
Massachusetts, USA) at room temperature (RT) for 8–9 h. IP3
response was measured on the Top counter (Perkin Elmer,
Massachusetts, USA).
2.7. Transcription factor reporter experiment
HEK293 cells were seeded out in 96 well plates (35,000/well)
(Sigma–Aldrich, MO, USA) 24 h prior to transfection. The cells were
transfected with increasing amount of GPR119 DNA or pcDNA3 (5,
10, 15 ng/well) together with cis reporter SRE/NFAT luciferase
(50 ng/well) or trans reporter CREB luciferase (6 ng/well CREB
+ 25 ng/well luciferase). The cells were incubated with and without
10 lM pertussis toxin (PTx, Sigma-Aldrich). 24 h after transfec-
tion the cells were washed in phosphate buffered saline (PBS, Dul-
becco) (Sigma–Aldrich, MO, USA), luminescence was measured at
the luminescence counter (Topcounter, Packard) (Perkin Elmer,
MA, USA) after 10 min incubation with 50 ll PBS + 50 ll Luciferase
lite substrate (Perkin Elmer, MA, USA).
2.8. Statistics
All data are presented as mean ± SEM. Statistical analysis
(unpaired t-test) was performed in Fig. 6 using Graph pad Prism
6. Statistically significant difference was observed as p < 0.05 (*),
p < 0.01 (**), p < 0.005 (***) or p < 0.001 (⁄⁄⁄⁄).
3. Results
3.1. Equal efficacies of OEA and AR231453 in G protein-dependent, as
well as G protein-independent pathways
We initially tested whether lipid-based and synthetic agonists
for GPR119 activate the same pathways. OEA was chosen due to
its previously described high potency [3–12] and tested in parallel
with the synthetic molecule AR231453 for the G protein-mediated
cAMP production and calcium release, as well as the G protein-
independent b-arrestin recruitment (Fig. 1). Consistent with previ-
ously published data [3–9,20], OEA and AR231453 initiated cAMPaccumulation in a dose-dependent manner with 33-fold higher
potency for AR231453 than that of OEA (Table 1) and with compa-
rable efficacies (Fig. 1A). A considerable basal constitutive activity
of 30% of the maximal stimulation by OEA (Emax) was observed
(Fig. 1A), consistent with the literature [8,13]. We next measured
the increase in intracellular calcium for both agonists and the
results were similar to those obtained from the cAMP accumulation
assay. This too was in agreement with previous results of an
OEA-induced GPR119 response [37]. AR231453 had a superior
potency compared to OEA with a 25-fold higher EC50 (Table 1) and
with comparable efficacies and a considerable constitutive activity
of30% of the Emax for OEAwas observed (Fig. 1B). The patent liter-
ature describes b-arrestin recruitment for cyanopyrazole-based
agonists through GPR119 [27], but nothing is known about other
synthetic molecules as well as lipid signaling through this pathway.
By employing stably transfected U2OS cells expressing GPR119, we
tested both ligands through this pathway. A robust activation with
similar efficacies was observed (Fig. 1C), and again AR231453 had
higher potency (166-fold) than OEA (Table 1). In this assay the
constitutive activity reached 60% of the Emax for OEA (Fig. 1C).
3.2. Expansion of the G protein-dependent signaling of GPR119
Besides Gas, a recent paper presented Gai as possible signaling
pathway for GPR119 [38], and also Gaq has been tested previously
[8]. We therefore looked more detailed into the G protein-signaling
profile of GPR119 in transiently transfected COS-7 cells. To mea-
sure Gaq activity, we investigated the IP3 turnover and as a posi-
tive control, we co-transfected with the chimeric Gqs5 G protein,
a Gaq subunit which contains the last 5 amino acids from Gas
(recognition motif for the Gas coupled receptors), and turns the
activity of a Gas-coupled receptor into a Gaq read-out [35]. Indeed,
both OEA and AR231453 increased IP3 turnover in a dose-
dependent manner with potencies similar to those observed in
the signaling pathways presented in Fig. 1, but with much lower
efficacies (7–10%) compared to the positive control (white sym-
bols, Fig. 2A and B, respectively and Table 1). The GIP receptor
was included as another control. Consistent with its Gas coupling
[39], co-transfection with Gqs5 resulted in a dose-dependent
response of GIP with similar potencies as described previously
[40], whereas no signaling was observed in the absence of Gqs5
(Fig. 2A and B). Due to the strong Gas coupling of GPR119
(Fig. 1), we decided to use an indirect measurement of Gai activity
by co-transfection with Gqi5, a Gaq subunit, which contains the
last 5 amino acids from Gai (recognition motif for the Gai coupled
receptors), and turns the activity of a Gai-coupled receptor into a
Gaq read-out [35]. Here, both OEA and AR231453, but not GIP
elicited a dose-dependent activation, indicating that GPR119 also
couples to Gai (Fig. 2C, Table 1). The efficacy was however much
lower, reaching levels of 27–40% of the positive controls
co-transfected with Gqs5. Similar results were found with the vari-
ant of Gqi5 denoted Gqi4myr (Table 1), and we thus had obtained
signaling data for GPR119 in Gas, Gaq and Gai in a highly compa-
rable setup, which is not found in earlier literature on GPR119.
3.3. Differential signaling pattern of GPR119 through an array of
transcription factors
Inspired by the broad G protein-signaling profile of GPR119, we
tested the receptor activity through a number of transcription
factors: CRE, NFAT and SRE in transiently transfected HEK293 cells.
These are controlled by different G proteins: Gas and Gaq (CRE),
Gaq and Gai (NFAT) and Gai and Ga12/13 (SRE) thereby repre-
senting a suitable battery for further signaling characterization of
GPR119. HEK293 cells were transfected with increasing amounts
of GPR119, and the basal activity was measured together with
Fig. 1. GPR119 activation by OEA and AR231453 via G protein-dependent and -independent pathways. cAMP formation (A), increased intracellular calcium (B) and b-arrestin
recruitment (C) induced by increasing doses of AR231453 (white) or OEA (black symbols) in COS-7 (cAMP and Ca2+), or in U2OS A2 (b-arrestin) cells transfected with GPR119
or empty vector pcDNA3 as negative control. Data are normalized to maximum OEA-induced GPR119 activity (100%) and pcDNA3.1 in the absence of ligand (0%). Data are
shown as mean ± SEM (n = 3–4). EC50 values and numbers of experiments are provided in Table 1. Chemical structures of OEA and AR231453 (D).
Table 1
Potencies of OEA and AR231453 in all implemented signaling pathways. From left column: experimental condition, signaling pathway, EC50, log EC50 ± SEM) and number of
experiments of OEA and AR231453. Upper third: GPR119 expressed alone. Middle third: GPR119 co-expressed with chimeric G proteins. Lower third: ligands administered
together with dose–response curves of OEA together with low (10 nM) and high (100 nM) concentrations of AR231453 (middle column) and dose–response or AR231453 together
with low (10 nM) and high (100 nM) OEA (right column).
Experimental condition Signaling pathway OEA AR231453
EC50 (lM) Log EC50 ± SEM N EC50 (nM) Log EC50 ± SEM N
GPR119 expressed alone cAMP 0.2 6.6 ± 0.2 4 6 8.2 ± 0.2 4
CRE 0.3 6.6 ± 0.9 5 57 7.3 ± 0.4 5
Calcium 1 6.0 ± 0.3 3 40 7.4 ± 0.8 3
IP3 0.9 6.0 ± 0.9 5 95 7.0 ± 0.7 5
SRE 15 4.8 ± 0.2 5 43 7.4 ± 0.2 5
b-arrestin 1 6.0 ± 0.1 4 6 8.2 ± 0.1 4
GPR119 co-expressed with chimeric G protein IP3 (+Gqs5) 0.085 7.0 ± 0.5 5 14 7.8 ± 0.2 3
IP3 (+Gqi5) 2 5.7 ± 0.2 5 52 7.3 ± 0.5 3
IP3 (+Gqi4myr) 1.8 5.7 ± 0.2 5 26 7.5 ± 0.2 3
Ligands co-administered cAMP (one ligand) 0.2 6.7 ± 0.4 5 20 7.7 ± 0.5 5
(10 nM co-ligand, low) cAMP (two ligands, low) 0,023 7.6 ± 0.6 5 3.5 8.5 ± 0.7 5
(100 nM co-ligand, high) cAMP (two ligands, high) 0,0037 8.4 ± 0.8 5 37 7.4 ± 0.5 5
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inverse agonist (0.1 lM AR436352) of GPR119 (Fig. 3). Confirming
the Gas activity, increasing doses of GPR119 resulted in an increase
in CRE-activation. At 10 ng GPR119, the AR231453-induced
activity was 20% higher than the basal activity, whereas the pres-
ence of AR436352 reduced the basal activity by 16% (Fig. 3A).
Intriguingly, no constitutive SRE activity was observed for
increasing concentrations of GPR119, whereas AR231453 induced
a substantial increase (Fig. 3B). As expected from the lack of the
basal activity through this signaling pathway, AR436352 had no
impact on the signaling through SRE (Fig. 3B). Like the
CRE-activity, NFAT was activated constitutively (agonist-
independent) in a gene-dose dependent manner (Fig. 3C). However
in contrast to the CRE-activity, NFAT activity could not be modu-
lated further by AR231453 or AR436352 (Fig. 3C). Knowing that
NFAT is mainly regulated by Gaq and Gai and due to the fact that
the activation of this pathway is mainly dependent on the GPR119
constitutive activity (Fig. 3C), NFAT activation was included to
confirm the Gai coupling observed using the Gaqi5 chimericsignaling (Fig. 2). To this end, we investigated the GPR119-
induced NFAT activation in the presence of the Gai inhibitor per-
tussis toxin (PTx). The PTx effect was investigated in comparison
to the two control receptors ORF74-human herpes virus (HHV) 8
and the ghrelin receptor. ORF74-HHV8 is constitutively active
through Gai and Gaq [41], whereas the ghrelin receptor facilitates
an efficacious Gaq signal [42]. PTx significantly inhibited the
GPR119-induced NFAT activation (in the absence of added ligand)
to the same extent as for ORF74-HHV8, whereas there was no
effect on the ghrelin receptor. The activity level of both GPR119
and ORF74-HHV8 was reduced to around 75% of the maximum
receptor activity when PTx was used, which confirms the observed
Gai signaling of GPR119 (Fig. 2).
3.4. Signaling pathway-dependent potencies of OEA, but not of
AR231453
The substantial variation in basal- and agonist-induced activity
among the three transcription factors (Fig. 3) urged further phar-
Fig. 2. Broad G protein-mediated signaling by GPR119. IP3 formation induced by increasing doses of OEA (A), AR231453 (B) or GIP (C) in COS-7 cells transfected with either
GPR119 (A and B) or the GIP receptor (C) alone (black triangles) or co-transfected with Gqi5 (black squares) or Gqsa5 (white circles). COS-7 cells transfected with GPR119 are
again pictured in Fig. 2D-F as a zoomed enlargement of the area between the dotted lines in Fig. 2A-C for a more detailed perspective. Data are shown as mean ± SEM (n = 3–
5). EC50 values and numbers of experiments are provided in Table 1.
Fig. 3. Constitutive and ligand-modulated transcriptional activity by GPR119. Transcription factor activity via CRE (A), SRE (B) and NFAT (C) in response to increasing doses of
GPR119 DNA (full lines) or pcDNA3 (dashes lines) in HEK293 cells. The cells were incubated for 5 h without (black symbols) or with (white symbols) AR231453 (square) or
AR436352 (triangle) at a concentration of 0.1 lM. Data are normalized to 10 ng GPR119 in the presence of AR231453 (100%). Data are shown as mean ± SEM, n = 4–5.
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OEA and the synthetic agonist AR231453 in a dose-dependent
manner for the two transcription factors (CRE and SRE) that were
responsive to AR231453 (Fig. 4). Consistent with the largely unal-
tered, and high potency of AR231453 through cAMP accumulation,
calcium release and b-arrestin recruitment (Fig. 1, Table 1),
AR231453 stimulated CRE and SRE with similar high potency
(Fig. 4A and B, Table 1). However, this was not the case for OEA,
as its potency through SRE activation was remarkably lower
(50-fold) compared to the CRE-activation (Fig. 4B, Table 1).
Notwithstanding, the efficacy of OEA was similar to that of
AR231453 (Fig. 4B). Thus OEA acts as a full agonist through SRE-
activation, despite a very low potency. Consistent with the gene-
dose experiments (Fig. 3), the basal activity leading to CRE-
activation was high, and reached 65% of the maximum activity
(Emax) induced by OEA, whereas no basal activity was observed
through SRE (<2% of the Emax for OEA (Fig. 4C)). Thus, the degree
of basal activity was congruent with the variation in OEA poten-
cies, as high potency was observed in the system with high basal
activities (CRE), whereas the absence of basal activity concurred
with a very low potency of OEA (Fig. 4D). The CRE and NFAT activ-
ity was measured in media containing 10% serum, while 0.5%serum was used for the SRE activity. To test if this low serum con-
centration was causing the low basal activity observed in SRE acti-
vation, we repeated the SRE activity in the presence of 10% serum.
Under these settings, the level of basal activity was comparable to
that in the presence of 0.5% serum, indicating no significant differ-
ence in the basal receptor activity in the presence of high serum
content (10%) and low serum content (0.5%).
Summarizing all data for the potencies of the two agonists and
the degree of constitutive activity obtained in the implemented
pathways, the fluctuations in EC50 values for AR231453 were small
(Fig. 5A), but varied a lot for OEA (Fig. 5B). Here, the highest poten-
cies were observed in Gas-mediated pathways (cAMP increase, IP3
measured by co-transfection with Gqs5 and the CRE transcription
factor), followed by assays mediated by Gaq (IP3 turnover and cal-
cium release) and lowest for Gai-mediated pathways (IP3 mea-
sured by co-transfection with Gqi5 and the SRE transcription
factor). Importantly, the percentage of constitutive activity relative
to the efficacy of OEA followed the same pattern, as high basal activ-
ity was observed in pathways with high potency of OEA, whereas it
dropped in pathways with low potency (Fig. 5C). This indicates that
the observed high basal activity of GPR119 could be caused by, or
influenced by lipids present in the cells or cell media – a
Fig. 4. Potencies of OEA and AR231453 in the CRE and SRE-transcription factors. Transcription factor CRE (A) and SRE (B) activation by increasing doses of OEA (closed circles)
or AR231453 (open circles) in HEK293 cells transfected with GPR119 or pcDNA3. Data are normalized to Emax for OEA (100%) and the activity of pcDNA (0%). Data are shown
as mean ± SEM, n = 8. Graphical illustrations of the degree of constitutive activity (black columns) relative to the Emax for OEA (100%) (C) and the potencies of AR231453 and
OEA (D).
Fig. 5. Overview of potencies and degree of constitutive activity for all pathways tested. Potencies of AR231453 (A) and OEA (B) in all included signaling pathways. From left
the Gas coupled pathways (CRE, IP3 measured by co-transfection with the chimeric Gqs5 and cAMP measurements), the Gaq coupled pathways (calcium release and IP3
measurements), the Gai coupled pathways (IP3 measured by co-transfection with the chimeric Gqi5 and Gqi4myr and the SRE transcriptional activity) and b-arrestin
recruitment. (C) Degree of constitutive activity relative to Emax of OEA in the same signaling pathways. Data are shown as mean ± SEM, n = 3–5.
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SRE-activation – in turn pointing at OEA as a biased ligand.
3.5. Endogenous lipids may contribute to the apparent high basal
activity of GPR119
To further assess the contribution of endogenous lipids in the
observed high basal activity, we included two inhibitors (JZL184
and URB597) for the enzymes responsible for the degradation of
2-MAGs and NAEs (i.e. MAGL and FAAH, respectively). Both inhibi-
tors were added 2 or 24 h before measuring the basal cAMP activity
in HEK293 cells transfected with either GPR119 or empty vector
control. None of the inhibitors had any impact on cAMP formation
in cells without GPR119 (Fig. 6, white bars), whereas the basal
activity of GPR119 (Fig. 6, black bars) was significantly (p < 0.01)
increased by pre-incubation with 0.1 lM JZL184 for 2 h (Fig. 6A)
and for 24 h (Fig. 6B). In contrast, 1 lM URB597 did not affect the
basal activity of GPR119 at any of these settings (Fig. 6C and D). This
indicates that endogenous 2-MAGs, but not NAEs, are generated
during a process of lipid metabolism in COS-7 cells, and may con-
tribute to the apparent constitutive activity of GPR119.
3.6. Agonist (-ago) allosteric modulation of OEA-induced GPR119
activation
As a consequence of the uncovering of endogenous lipids as
putative players in the observed high basal activity of GPR119(Fig. 6), we decided to test whether the synthetic agonist
AR231453 acted as allosteric modulator of the lipid-induced
activity. A series of dose–response curves for OEA-induced cAMP
formation was performed in the absence and presence of low
(10 nM) or high (100 nM) concentration of AR231453. Both con-
centrations of AR231453 increased the potency positively with 8-
fold increase in the presence of 10 nM AR231453, and more than
50-fold for 100 nM AR231453 (p < 0.05) (Fig. 7A, Table 1). This
was not the case in the opposite situation (Fig. 7B, Table 1). Thus,
AR231453 seems to act as a positive allosteric modulator of OEA,
concomitant with being an agonist itself.4. Discussion
In the present study, we extend the signaling profile of GPR119
to include not only Gas, but also other G proteins, transcription
factors as well as b-arrestin recruitment. The endogenous OEA
and the synthetic AR231453 were full agonists through most path-
ways, and whereas the potency of AR231453 was rather constant,
that of OEA varied in a pathway-dependent manner, that paralleled
the basal receptor activity. This establishes OEA as a biased ligand.
Together with the observation that endogenous MAGs influence
the basal activity of GPR119, this indicates that the basal activity
of GPR119 is – in part – mediated by endogenous lipids. Finally,
AR231453 was shown to act as a positive allosteric modulator of
OEA activity.
Fig. 6. Impact on the constitutive activity of GPR119 by inhibition of MAG and NAE degradation. cAMP formation in COS-7 cells transfected with GPR119 (black columns) or
pcDNA3 (white columns) in the presence and absence of the monoacylglycerol (MAG) lipase inhibitor JZL184, 0.1 lM (A and B) or the FAAH inhibitor URB597, 1 lM (C and D),
for 2 h (A and C) or 24 h (B and D). Data are normalized to the basal activity of GPR119 in the absence of inhibitors (100%) and zero (0%) and shown as mean ± SEM, n = 3. The
unpaired t-test was used to test for statistical significance (p < 0.05⁄, <0.01⁄⁄, <0.005⁄⁄⁄ and <0.0001⁄⁄⁄⁄).
Fig. 7. Allosteric modulation of GPR119. cAMP formation in transiently transfected COS-7 cells was stimulated by increasing concentrations of OEA (A) or AR231453 (B) with
or without co-administration of fixed concentrations of OEA (1 lM and 0.1 lM) (B) or AR231453 (10 nM/0.1 lM) (A). Data are normalized to Emax of OEA (100%) and pcDNA-
transfected cells (0%). Data are shown as mean ± SEM, n = 5.
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The signaling through Gas is well established for GPR119
[3,8,9,12,13,21–23], and we confirm this both by direct cAMP mea-
surements and by CRE activity. Gas signaling has been shown to be
a driving pathway for the insulinotropic effect of many GPCRs likeGPR119 and TGR5 expressed in pancreatic b-cells and for GLP-1
release from EECs in the gut [8,13]. However, growing evidence
suggests that Gas and Gaq may act in synergy on hormone
secretion for instance via a cAMP-mediated potentiation of
glucose-induced insulin secretion triggered by intracellular Ca2+
through the ATP-sensitive potassium channel and opening of
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[43], as recently described for GPR40 [44]. Gaq activity has not
been observed before for GPR119. In the present study, we
observed a minute Gaq coupling measured by IP3 turnover, yet
the robust agonist-induced calcium release and basal NFAT activity
supports this activity. It should be noted however, that calcium
release as well as NFAT activation can be mediated not only by
Gaq, but also by for instance Gas and Gai (for calcium release)
and Gai (for NFAT activity) [41–46]. It is therefore likely that the
strong calcium release reported here and previously [24,26] is
mediated not only by Gaq activity, but also by the other pathways.
It is possible that the Gaq activity may contribute to, and maybe
even synergize, the insulinotropic action of GPR119 as in GPR40
[44]; however like in GPR40, where Gas is the main insulinotropic
pathway [44], the Gas activity of GPR119 is far superior to that of
Gaq. The Gai activity observed here, and previously [38], by IP3
release during co-transfection setups with Gqi5 and confirmed
with the inhibition of the receptor-induced NFAT activation in
the presence of the Gai inhibitor PTx is somehow paradoxical to
the strong Gas coupling. However, dual coupling to these two G
proteins have been observed before in for instance the adrenergic
A2a receptor with the most potent activation through Gai and a
weaker signaling through Gas [47,48]. In this receptor, distinct
regions of selective coupling to these two G proteins were identi-
fied in ICL2 and ICL3 [49,50]. The M2 and M4 muscarinic receptors
display similar dual coupling with the same preponderance toward
Gai coupling [51], whereas the GnRH receptors in addition to Gaq,
couples to Gas and Gai, where the Gas coupling occurs with higher
potency than the Gai activity [52] (like for GPR119, Fig. 5). It can be
envisioned that the dual regulation of the activity of adenylate
cyclase may fine-tune the downstream signaling in GPR119 and
thereby provide a more tightly regulated hormone release, as
shown in the GnRH receptor, where the dual action is necessary
for the pulsatile hormone release [52]. In support of this as a rele-
vant mechanism for GPR119, it was shown earlier that epinephrine
administration to pancreatic a-cells resulted in both Gai and Gas
activation by the A2a receptor [53].
4.2. The role of b-arrestin recruitment for GPR119 action
Classically, b-arrestin recruitment is an initial step in receptor
desensitization and subsequent internalization [54,55], yet it may
also be involved in the initiation of G protein-independent signal-
ing pathways, like MAP-kinases [56]. b-Arrestin recruitment by
lipids acting via GPR119 has never been described before. We
observed potent activation via this pathway for both ligands and
thereby show for the first time, that also endogenous lipids acti-
vate recruitment of b-arrestin via GPR119. However it remains to
be determined if this signaling of GPR119 is involved in its biolog-
ical effects similar to the reported involvement of GLP-1 receptor-
mediated b-arrestin recruitment for insulin release from pancre-
atic b-cells [57]. In support of the relevance of b-arrestin recruit-
ment for GPR119, a recent publication described desensitization
of GPR119 by different synthetic agonists [58]. Furthermore, the
strong b-arrestin coupling by GPR119 may be involved in the high
degree of constitutive internalization, rapid recycling and prefer-
ential intracellular location of GPR119 [59], a distribution also
known for other constitutively active GPCRs, like the viral US28
chemokine receptor [60,61].
4.3. Ligand-bias of OEA and apparent constitutive activity of GPR119
Signaling bias describes a situation where different ligands eli-
cit different signals through a given receptor (ligand bias), when
the same ligand acts on different receptors with different signaling
outcomes (receptor bias) or when a given ligand-receptor pairresults in different signaling outcome in an expression-
dependent manner (tissue/cell bias) [62]. In contrast to the
potency of AR231453, that only varied very little, consistent with
previous data [8–13], the potency of OEA was pathway-
dependent and thereby acted as a biased ligand with the same effi-
cacy as AR231453 in all tested pathways. The highest potency of
OEA was observed in Gas-dependent pathways, where previously
reported potencies were confirmed [3,12,28] followed by the
Gaq-mediated pathways, and with lowest potency via Gai
(Fig. 5, Table 1). The lowest potency was observed in the SRE path-
way concomitant with a complete lack of constitutive activity,
whereas the Gas-mediated pathways displayed the highest degree
of constitutive activity concomitant with the highest OEA poten-
cies. Thus, the observed constitutive activity via Gas correlates
with the biased action of this endogenous lipid. This was further
emphasized by the increase in activity upon pre-incubation with
JZL184 – an inhibitor of the enzyme MAGL that degrades 2-
MAGs, demonstrating that endogenous MAGs are indeed produced
in a common (fibroblast-like) cell line, and implying that MAGs
potentially contribute to the observed basal activity of GPR119 in
any cells that employ lipoprotein lipase to metabolize lipids, if they
negatively regulate MAGL activity. Interestingly, we could not
determine that NAEs play the same role, as the NAE inhibitor
URB597 did not affect GPR119 signaling, which could both indicate
that NAEs are not being produced – or degraded – endogenously in
our setup.
Constitutive activity is commonly observed among GPCRs as for
example the ghrelin receptor [42], and many virus-encoded recep-
tors [63,64,46,65]. However, apparent constitutive activity may be
a result of – or at least influenced by – endogenous agonist(s) pre-
sent in the media or in the cells that may lead to receptor activity,
thereby masking the ‘‘true” pharmacology of a given receptor – a
situation that our results indicate for GPR119. This was for instance
the case for GPR40 (FFAR1); another lipid receptor with similar
expression pattern as GPR119 and similar insulinotropic action
mediated via Gas and Gaq activation by FFA [44,66]. In GPR40,
FFA in the added serum, resulted in an apparent high constitutive
activity, that was eliminated in fatty acid-depleted serum [29].
Another example is the lipid receptor GPR183 (also known as
Epstein Barr virus-induced receptor 2, EBI2). Prior to its deorpha-
nization as a receptor for oxysterols [67,68], high constitutive
Gai activity was observed in several cell lines [30,69]. However,
this activity was, at least in part, mediated by oxysterols in the
medium/cells as an inhibition of the CYP7B1 enzyme, involved in
oxysterol formation, by clotrimazole, reduced EBI2 activity
[30,68,69].
4.4. Intrinsic and allosteric actions of GPR119 agonists
In the present study we observed that, besides its intrinsic
activity, AR231453 acted as a positive allosteric modulator of
OEA. A recent study by Zhang et al. also investigated the putative
synergy between these two ligands, not by a direct measurement
of cAMP accumulation as it is the case here, but by measuring
downstream signaling mediated by the induced cAMP, i.e. the tran-
scription factor CRE [70]. In contrast to our data, they did not
observe any allosteric action of AR231453. This however could be
due to insufficient amounts of AR231453 in their studies (0.008–
1 nM) as compared to the concentrations used in our study (10
and 100 nM); differences that may have an even higher impact
given the chosen experimental settings, as AR231453 displays a
10-fold lower potency in the CRE transcription factor assay than
in the cAMP accumulation assay (Table 1). The structural basis
for this allosteric action of AR231453 is rather challenging, as a
recent study described largely overlapping binding pockets for
AR231453 and OEA, yet with minor differences in that AR231453
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interaction with residues as deep as position III:09 and III:12
(3.36 and 3.39, respectively) [28]. Furthermore, OEA is a highly
flexible ligand that may allow several binding poses, some of
which could permit the action of AR231453 at the same time, or
it could be envisioned that AR231453 constrains the receptor in
an OEA-preferential conformation. Interestingly, a large degree of
overlap was identified for residues involved in binding of OEA
and AR231453 and residues involved in the constitutive activity
[28], again pointing toward a possible role of endogenous lipids
as contributors to the apparent high constitutive activity of
GPR119.4.5. Perspectives
Owing to the expression pattern and physiological role of
GPR119, this receptor is an attractive metabolic target – an insu-
linotropic ‘‘lipid sensor” in the gut with 2-OG as the most rele-
vant food-derived ligand [5,14] recently proven to act in vivo
in humans [3]. Exogenous OEA has also been proven effective
in vivo in rodent studies [12,15], but it is unclear whether
endogenous OEA participate in activation of GPR119. The
observed positive allosteric action of AR231453 is important,
as allosteric modulation drugs encompass obvious advantages
as compared to orthosteric counterparts by potentially modulat-
ing and fine tune the action of the endogenous ligands, possibly
without the same risk of overdosing effects and with an action
that depends on the endogenous ligands. However, allosteric
action by a ligand may also possess intrinsic activity, as in the
case of AR231453. We also show that endogenous lipids may
contribute to the apparent constitutive activity of GPR119. An
intriguing question is therefore whether AR231453 indeed pos-
sesses intrinsic activity, or whether its observed agonism is a
result of an allosteric action of the effect of endogenous lipids.
Further studies are needed to clarify this. From a clinical point
of view, synthetic GPR119 agonists have not yielded much suc-
cess yet and in fact several studies have been disappointing
[16,18,19]. Thus, we are still waiting for a successful outcome
of clinical trials for GPR119 agonists. The lack of success –
despite numerous potent GPR119 agonists – could be due to
inadequate characterization of basic pharmacological properties
of these compounds, hereunder allosteric actions and well-
defined pathway targeting, maybe in the sense of biased drugs
targeting one or several of the pathways described in the current
study.Disclosures
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